FeesSafety
Pluang+

EZCORP posts 33% revenue growth and 46% EPS rise in fiscal 2026, driven by core pawn business expansion.

Company Fundamentals
11 Nov 2026, 23:09 WIB
GlobeNewsWire
View Source
Bullish
EZCORP posts 33% revenue growth and 46% EPS rise in fiscal 2026, driven by core pawn business expansion.

EZCORP reported a strong fiscal 2026 with total revenues up 33% to $1.69 billion and net income rising 51% to $165.9 million, driven by growth in its core pawn operations across the U.S., Latin America, and the Caribbean. The company expanded its store footprint by 230 locations, including the full acquisition of SMG, boosting pawn loans outstanding by 31%. CEO Lachie Given highlighted robust lending, merchandise sales, and margin improvements as key drivers, with plans to continue expanding and integrating acquisitions in fiscal 2027. This performance underscores EZCORP's scalable business model and positions it for sustained growth and shareholder value.

EZCORP's fiscal 2026 results provide context as of Nov 12, 2026 03:31 WIB. For readers following Financials-sector US stocks on Pluang, 96 of 142 stocks rose and 45 fell today. Notable movers include CLSK at USD 6.90 with a 5.02% increase, PURR at USD 9.17 with a 4.80% rise, and HOOD at USD 85.23 also up 4.80%.

More News

Global beverage market to reach $2.78T by 2032, driven by nonalcoholic drinks and convenience trends.

Global beverage market to reach $2.78T by 2032, driven by nonalcoholic drinks and convenience trends.

The global beverage market is projected to grow from $2.03 trillion in 2026 to $2.78 trillion by 2032, at a CAGR of 5.35%. Growth is fueled by rising demand for nonalcoholic and functional beverages, convenience packaging, and premium products for sp...

Market News
Bullish
2 hours ago
Over 200 GLP-1 and incretin therapies in development are reshaping diabetes and obesity treatment landscapes.

Over 200 GLP-1 and incretin therapies in development are reshaping diabetes and obesity treatment landscapes.

DelveInsight's 2026 report reveals more than 200 GLP-1 receptor agonists and incretin-based therapies are in development by over 180 companies, targeting conditions like type 2 diabetes, obesity, and related metabolic disorders. Key players such as E...

Bullish
3 hours ago
Innovative Holdings Alliance rebrands as Premergy, shifts focus to battery tech under new ticker PMGY.

Innovative Holdings Alliance rebrands as Premergy, shifts focus to battery tech under new ticker PMGY.

Innovative Holdings Alliance, Inc. has changed its name to Premergy, Inc. and will trade under the new ticker symbol PMGY starting November 12, 2026. This rebranding aligns the company with its focus on advanced battery technology and power-managemen...

Company Fundamentals
Neutral
5 hours ago
AMH declares Q4 2026 dividend of $0.33 per common share, payable Dec 31.

AMH declares Q4 2026 dividend of $0.33 per common share, payable Dec 31.

AMH announced a dividend of $0.33 per common share for Q4 2026, payable in cash on December 31 to shareholders of record as of December 15. Additionally, quarterly distributions were declared for preferred shares: $0.36719 for Series G and $0.39063 f...

Company Fundamentals
Neutral
5 hours ago
AirSculpt launches first nationwide Open House event to boost body contouring awareness and patient engagement

AirSculpt launches first nationwide Open House event to boost body contouring awareness and patient engagement

AirSculpt Technologies is hosting its first nationwide Open House event, "The Gift of Body Confidence," on November 12, 2026, across 31 centers and online. The event offers personalized consultations, educational sessions, and Q&A with surgeons, high...

Market News
Bullish
5 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App